SYGNIS AG extends OEM agreement with leading global research tools provider

Heidelberg, Germany and Cambridge, UK, 21 February 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has signed an extended OEM agreement with one of its key strategic partners, a leading global research tools provider to the life science industry.

The new two-year rolling contract is expected to grow SYGNIS’ revenues through this customer channel by 35% per annum, to over € 800,000, resulting from increased access to new product lines and the extension of the scope of the Company’s long term commercial arrangements.

SYGNIS is also in late stage negotiations with the partner organisation for supply and licensing agreements, which will see Expedeon’s Lightning-Link® technology embedded into the partner’s commercially available research assays, thereby securing a minimum five-year revenue stream from royalties and license fees which will contribute a further 2-4% to SYGNIS’ revenue.

Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, said: “The continuation and expansion of this OEM agreement with a valued partner underlines the importance of the Expedeon products to the life sciences industry. The extended contract offers the opportunity to drive sales revenue growth, whilst providing customers with improved access to innovative research tools via our partner’s worldwide sales and distribution channels. This agreement also underscores the significant organic growth opportunities available within our product portfolio.

SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and
proteomics research based on its proprietary technologies, offering a wide range of solutions that
address key challenges in molecular biology. With applications spanning the entire molecular biology
workflow, the Group’s cutting-edge offerings include easy-to-use off-the-shelf products as well as
custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS’
products are sold through a direct sales force and several distribution partners in Europe, the USA and
Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the
Expedeon, Expedeon and C.B.S. Scientific brands. The Company is listed on the Prime
Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).